ARIAD Pharma (ARIA) Tops Q1 EPS by 3c; Revises Certain FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review
May 10, 2016 7:35 AM EDT~Recorded Net Product Revenue of $33.6 million for the first quarter of 2016; growth of 41% from prior year
~Provides guidance for 2016, including strengthened year-end cash position, following announced Incyte transaction:
Global product and royalty revenue of $170 million to $180 million R&D expense of $175 million to $180 million SG&A expense of $120 million to $125 million Year-end cash of $280 million to $290 million~Conference Call Scheduled Today at 8:30 a.m. ET... More
